Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Vutiglabridin (HSG4112) in Healthy and Obese Males
NCT04732988Phase 1Completed
- Sponsor
- Glaceum
- Start
- Aug 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vutiglabridin in obesity (17 arms), sponsored by Glaceum. Primary endpoints: Area Under the Plasma Concentration-Time Curve Over Dosing Interval, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Point and 11 more. Started Aug 2018; status: completed.
02
Drugs
vutiglabridin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04732988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732988.